Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$88.74 USD

88.74
1,093,175

+4.62 (5.49%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $88.71 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (214 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors are optimistic about Exact Sciences (EXAS) led by continued strength across the Screening and Precision Oncology businesses.

Neogen (NEOG) Launches Genomic Test for Beef-on-Dairy Calves

Neogen's (NEOG) new Igenity BeefXDairy test is an additional tool, enabling producers to gather crucial data they need to advance and grow their operations effectively and sustainably.

Masimo's (MASI) New FDA Approval to Boost Patient Monitoring

Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.

Penumbra (PEN) Launches New Technology for Blood Clot Removal

Penumbra (PEN) launches Lightning Bolt 7, a new technology that can remove blood clots faster and more efficiently with modulated aspiration.

Here's Why You Should Retain McKesson (MCK) Stock for Now

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Revvity (RVTY) Launches New System for Autoimmune Diagnostics

Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.

HealthEquity (HQY) Surpasses Q1 Earnings Estimates, FY24 View Up

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2024.

Here's Why You Should Hold Integer Holdings (ITGR) Stock for Now

Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.

Thermo Fisher's (TMO) Unveils Orbitrap Astral Spectrometer

Thermo Fisher's (TMO) OrbitrapTM AstralTM mass spectrometer enables accurate and exact quantification in proteomics laboratories.

Hologic (HOLX) Stock Up 5.6% YTD: Will the Rally Continue?

The higher capital equipment revenues, procedural volumes return and an acceleration from the new business lines poise Hologic (HOLX) for future growth.

Here's Why You Should Hold on to Align Technology (ALGN) Now

Investors are optimistic about Align Technology (ALGN) owing to expanding work-flow options of its leading iTero scanners.

Here's Why You Should Retain AMN Healthcare (AMN) Stock for Now

Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.

Illumina's (ILMN) New AI Tool to Predict Genomics Disease

Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.

Here's Why You Should Retain PacBio (PACB) Stock for Now

PacBio's (PACB) product development activities raise optimism about the stock.

Haemonetics (HAE) Hospital Arm Grows, Plasma Volume Improves

Within Haemonetics (HAE) Vascular Closure, growth is led by the opening of new accounts and increasing penetration to gain share in the top U.S. EP hospitals.

Charles River (CRL) to Build RightSource Lab With New Pact

Charles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership.

Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY24 Outlook

Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both segments.

Here's Why You Should Retain DaVita (DVA) Stock for Now

Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.

Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses

Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.

Veeva Systems (VEEV) Extends Tie-Up With Lotus Clinical

Veeva Systems (VEEV) expands its partnership with Lotus Clinical to accelerate clinical trials.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.

Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?

Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.

Stryker's (SYK) Q Guidance Successful in First Surgery

Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.

Catalent (CTLT) Expands Its Facility Capabilities in Shiga

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.